3.

Triglyceride lowering efficacy of fluvastatin
Patient or population: participants with normal or abnormal lipid profiles Settings: ambulatory care Intervention: fluvastatin Comparison: Triglyceride percentage change from baseline for all trials
Outcomes	Anticipated absolute effects mmol/L (95%CI)		Percent Reduction (95% CI) %	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Before exposure to fluvastatin1	After exposure to fluvastatin
Triglycerides fluvastatin 10 mg/day	1.93 (1.63 to 2.22)	1.87 (1.73 to 2.01)	3.0 (10.1 to ‐4.2)	259 (3)	⊕⊕⊕⊕ high	Effect predicted from log dose‐response equation is 5.2%. Only RCT data.
Triglycerides fluvastatin 20 mg/day	1.98 (1.68 to 2.28)	1.76 (1.74 to 1.77)	11.1 (11.8 to 10.3)	7510 (39)	⊕⊕⊕⊕ high	Effect predicted from log dose‐response equation is 9.4%. Randomised and before and after design not different P = 0.277.
Triglycerides fluvastatin 40 mg/day	1.94 (1.70 to 2.17)	1.72 (1.69 to 1.75)	11.1 (12.6 to 9.6)	2646 (48)	⊕⊕⊕⊕ high	Effect predicted from log dose‐response equation is 13.6% Randomised and before and after design not different P = 0.186.
Triglycerides fluvastatin 80 mg/day	1.92 (1.67 to 2.17)	1.59 (1.56 to 1.62)	17.5 (19.1 to 15.9)	3623 (23)	⊕⊕⊕⊕ high	Effect predicted from log dose‐response equation is 17.7% Randomised and before and after design not different P = 0.496.
CI: Confidence interval
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

1. Mean baseline values.